Jury Member Start-up Pitch Contest & Investors Table

Jaap de Bruin | Investment Manager FIRST fund | FIRST fund at BioGeneration Ventures

Jaap is Investment Manager, leading BGV’s Fonds InvesteringsRijpe Starters (FIRST) fund. He joins BGV from Utrecht Health Seed Fund where he was Fund Manager with oversight for a series of successful investments in health and life sciences companies such as TargED Biopharmaceuticals, NTrans Technologies and Moveshelf. Prior to this, Jaap was an Investment Manager and Senior Business Developer at Utrecht Holdings where he led a number of investments, including the investment in Quantib, which was successfully sold to RadNet, Inc. He directed over 15 intellectual property tech license deals including the MR-STAT technology to Philips Healthcare. Prior to this, Jaap held several roles at Philips Healthcare’s Image Guided Therapy business and corporate incubator. Jaap holds a master’s degree in Aerospace Engineering from Delft University of Technology.

About FIRST fund at BioGeneration Ventures

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies.With a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies, BGV manages over €440 million across 5 fund, and invests in areas where true scientific innovations, unmet medical needs, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to progress science and build successful companies and uses its experience to guide progress into clinical trials, leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. BGV operates a joint venture partnership with Forbion. The Company is based in Naarden, The Netherlands. For more information, please visit: http://www.biogenerationventures.com.

BioGeneration Ventures’ FIRST Fund (Fonds InvesteringsRijpe Starters) is a pre-seed fund that finances pioneering scientists in The Netherlands who are active in the emerging fields of regenerative medicine and cardiovascular diseases. FIRST supports leading scientists in these fields to transform their breakthrough discoveries into sustainable, innovative companies that can develop the products needed to improve patient’s lives. We harness innovative science to foster its development into a product vision, and with our extensive network, attract follow-on investments.

FIRST is founded by the Dutch CardioVascular Alliance (DCVA) and Regenerative Medicine Crossing Borders (RegMed XB) with support of the Dutch Ministry of Economic Affairs and Climate Policy (under the TTT-regeling). The DCVA and RegMed XB are public-private partnerships that bring together the best scientists in The Netherlands to discover new regenerative and cardiovascular medicine and solutions to prevent and cure chronic diseases.